Low-grade non-Hodgkin's lymphoma in northern Norway: treatment, outcome, and prognostic factors. 1998

R M Bremnes, and A Vik, and N Helbekkmo
Department of Oncology, University Hospital of Tromsø, Norway. kreftrmb@rito.no

OBJECTIVE All low-grade non-Hodgkin's lymphoma (LG-NHL) patients diagnosed and/or treated at our institution over a 10 year period were investigated with regard to treatment outcome and possible pre-treatment prognostic factors. METHODS During the period 1986-1995, 169 consecutively registered patients with LG-NHL were retrospectively analyzed with regard to personal, treatment, and disease- specific characteristics. The median follow-up time was 52 months (5-132 months). All patients were diagnosed histologically according to the Keil classification system. Median age was 60 years (range 27-87 years), and the male:female ratio was 1.05: 1. RESULTS The overall response rate was 77%, of which 66% were complete response (CR) and 11% partial response (PR). 5- and 10-year overall survival were 72% and 47%, respectively, and median overall survival was 8.3 years. 10-year overall survival for stage I, II, III, and IV were 86%, 65%, 33%, and 29%, respectively. For follicular lymphoma, 10-year survival was 52% and median survival 12.5 years. In univariate analysis, the following pre-treatment factors indicated a poor prognosis: advanced stage, general symptoms, bone marrow infiltration, poor performance status, tumor > or = 6 cm, low serum albumin, anaemia, and LDH > or = 540 U/l. In multivariate analysis, stage, performance status, tumor size, and anaemia were found to be independent prognostic factors for overall survival. CONCLUSIONS The treatment strategy has proved successful for most patients with localised disease. Independent prognostic indicators for survival as stage, performance status, tumor size, and anaemia may be useful guides in deciding when and how to treat.

UI MeSH Term Description Entries
D008228 Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. Non-Hodgkin Lymphoma,Diffuse Mixed Small and Large Cell Lymphoma,Diffuse Mixed-Cell Lymphoma,Diffuse Small Cleaved-Cell Lymphoma,Diffuse Undifferentiated Lymphoma,Lymphatic Sarcoma,Lymphoma, Atypical Diffuse Small Lymphoid,Lymphoma, Diffuse,Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic,Lymphoma, High-Grade,Lymphoma, Intermediate-Grade,Lymphoma, Low-Grade,Lymphoma, Mixed,Lymphoma, Mixed Cell, Diffuse,Lymphoma, Mixed Lymphocytic-Histiocytic,Lymphoma, Mixed Small and Large Cell, Diffuse,Lymphoma, Mixed-Cell,Lymphoma, Mixed-Cell, Diffuse,Lymphoma, Non-Hodgkin's,Lymphoma, Non-Hodgkin, Familial,Lymphoma, Non-Hodgkins,Lymphoma, Nonhodgkin's,Lymphoma, Nonhodgkins,Lymphoma, Pleomorphic,Lymphoma, Small Cleaved Cell, Diffuse,Lymphoma, Small Cleaved-Cell, Diffuse,Lymphoma, Small Non-Cleaved-Cell,Lymphoma, Small Noncleaved-Cell,Lymphoma, Small and Large Cleaved-Cell, Diffuse,Lymphoma, Undifferentiated,Lymphoma, Undifferentiated, Diffuse,Lymphosarcoma,Mixed Small and Large Cell Lymphoma, Diffuse,Mixed-Cell Lymphoma,Mixed-Cell Lymphoma, Diffuse,Non-Hodgkin's Lymphoma,Reticulosarcoma,Reticulum Cell Sarcoma,Reticulum-Cell Sarcoma,Sarcoma, Lymphatic,Sarcoma, Reticulum-Cell,Small Cleaved-Cell Lymphoma, Diffuse,Small Non-Cleaved-Cell Lymphoma,Small Noncleaved-Cell Lymphoma,Undifferentiated Lymphoma,Diffuse Lymphoma,Diffuse Lymphomas,Diffuse Mixed Cell Lymphoma,Diffuse Mixed-Cell Lymphomas,Diffuse Small Cleaved Cell Lymphoma,Diffuse Undifferentiated Lymphomas,High-Grade Lymphoma,High-Grade Lymphomas,Intermediate-Grade Lymphoma,Intermediate-Grade Lymphomas,Low-Grade Lymphoma,Low-Grade Lymphomas,Lymphatic Sarcomas,Lymphocytic-Histiocytic Lymphoma, Mixed,Lymphocytic-Histiocytic Lymphomas, Mixed,Lymphoma, Diffuse Mixed-Cell,Lymphoma, Diffuse Undifferentiated,Lymphoma, High Grade,Lymphoma, Intermediate Grade,Lymphoma, Low Grade,Lymphoma, Mixed Cell,Lymphoma, Mixed Lymphocytic Histiocytic,Lymphoma, Non Hodgkin,Lymphoma, Non Hodgkin's,Lymphoma, Non Hodgkins,Lymphoma, Nonhodgkin,Lymphoma, Small Non Cleaved Cell,Lymphoma, Small Noncleaved Cell,Lymphosarcomas,Mixed Cell Lymphoma,Mixed Cell Lymphoma, Diffuse,Mixed Lymphocytic-Histiocytic Lymphoma,Mixed Lymphocytic-Histiocytic Lymphomas,Mixed Lymphoma,Mixed Lymphomas,Mixed-Cell Lymphomas,Non Hodgkin Lymphoma,Non Hodgkin's Lymphoma,Non-Cleaved-Cell Lymphoma, Small,Non-Hodgkins Lymphoma,Noncleaved-Cell Lymphoma, Small,Nonhodgkin's Lymphoma,Nonhodgkins Lymphoma,Pleomorphic Lymphoma,Pleomorphic Lymphomas,Reticulosarcomas,Reticulum Cell Sarcomas,Reticulum-Cell Sarcomas,Sarcoma, Reticulum Cell,Small Cleaved Cell Lymphoma, Diffuse,Small Non Cleaved Cell Lymphoma,Small Non-Cleaved-Cell Lymphomas,Small Noncleaved Cell Lymphoma,Small Noncleaved-Cell Lymphomas,Undifferentiated Lymphoma, Diffuse,Undifferentiated Lymphomas
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009664 Norway A country located in northern Europe, bordering the North Sea and the Atlantic Ocean, west of Sweden. The capital is Oslo. Kingdom of Norway
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

R M Bremnes, and A Vik, and N Helbekkmo
January 1999, Acta oncologica (Stockholm, Sweden),
R M Bremnes, and A Vik, and N Helbekkmo
February 1992, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
R M Bremnes, and A Vik, and N Helbekkmo
January 1993, Acta oncologica (Stockholm, Sweden),
R M Bremnes, and A Vik, and N Helbekkmo
February 1989, British journal of cancer,
R M Bremnes, and A Vik, and N Helbekkmo
January 1997, Acta oncologica (Stockholm, Sweden),
R M Bremnes, and A Vik, and N Helbekkmo
June 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R M Bremnes, and A Vik, and N Helbekkmo
January 1996, Acta oncologica (Stockholm, Sweden),
R M Bremnes, and A Vik, and N Helbekkmo
May 1991, Recenti progressi in medicina,
R M Bremnes, and A Vik, and N Helbekkmo
May 1985, The New England journal of medicine,
R M Bremnes, and A Vik, and N Helbekkmo
August 2001, Cancer research and treatment,
Copied contents to your clipboard!